Best of Biosimilars Coverage in 2022

Matthew Lee, vice president of sales and marketing at MedOne, led a discussion about trends in care management from a PBM and health perspective.

The clinical pharmacist will play an important role as a medication expert, filling in for the role that pharmaceutical manufacturers once did in supporting patients and prescribers.

Sandoz's injection treatment natalizumab-sztn (Tyruko) is the first biosimilar approved by the health agency for the treatment of multiple sclerosis.

Researchers at the 2023 American Academy of Dermatology Association Annual Meeting discussed the effects of product complexity on preclinical testing, among other topics.

The news comes almost 2 weeks after Cyltezo’s entrance into the US biosimilars market as the first commercially available and FDA-approved interchangeable adalimumab biosimilar.

The company will also add Sandoz’s unbranded version of adalimumab to its National Preferred Formulary.